Identification of New Candidate Therapeutic Target Genes in Triple-Negative Breast Cancer

Genes and Cancer

Volumn 3, Issue 1, 2012, Pages 63-70

  Glénisson, Mathilde ^a   Vacher, Sophie ^a   Callens, Céline ^a   Susini, Aurélie ^a   Cizeron Clairac, Géraldine ^a   Le Scodan, Romuald ^a   Meseure, Didier ^a   Lerebours, Florence ^a   Spyratos, Frédérique ^a   Lidereau, Rosette ^a   Bièche, Ivan ^a  

^a INSTITUT CURIE   (France)

Author keywords

breast cancer; therapeutic target; triple negative

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; FOCAL ADHESION KINASE 1; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; VASCULOTROPIN A;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FGFR3 GENE; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE; ONCOGENE SRC; PARP1 GENE; PIK3CA GENE; PRIORITY JOURNAL; PTK2 GENE; RAF1 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; VEGFA GENE;

EID: 84868644233     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912449832     Document Type: Article

References (41)

1. Lumachi F,Luisetto G,Basso SM,Basso U,Brunello A,Camozzi V.Endocrine therapy of breast cancer.Curr Med Chem. 2011;18:513-22.
2. Awada A,Bozovic-Spasojevic I,Chow L.New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? Cancer Treat Rev.Epub. 2012;:2.
3. Cleator S,Heller W,Coombes RC.Triple-negative breast cancer: therapeutic options.Lancet Oncol. 2007;8:235-44.
4. Pal SK,Mortimer J.Triple-negative breast cancer: novel therapies and new directions.Maturitas. 2009;63:269-74.
5. Podo F,Buydens LM,Degani H,et al.Triple-negative breast cancer: present challenges and new perspectives.Mol Oncol. 2010;4:209-29.
6. Lehmann BD,Bauer JA,Chen X,et al.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.J Clin Invest. 2011;121:2750-67.
7. Sorlie T,Perou CM,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci U S A. 2001;98:10869-74.
8. Ma CX,Luo J,Ellis MJ.Molecular profiling of triple negative breast cancer.Breast Dis. 2010;32:73-84.
9. Atchley DP,Albarracin CT,Lopez A,et al.Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.J Clin Oncol. 2008;26:4282-8.
10. Toyama T,Yamashita H,Kondo N,et al.Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.BMC Cancer. 2008;8:309.
11. Tutt A,Robson M,Garber JE,et al.Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.Lancet. 2010;376:235-44.
12. O'Shaughnessy J,Osborne C,Pippen JE,et al.Iniparib plus chemotherapy in metastatic triple-negative breast cancer.N Engl J Med. 2011;364:205-14.
13. Javle M,Curtin NJ.The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.Ther Adv Med Oncol. 2011;3:257-67.
14. Liedtke C,Mazouni C,Hess KR,et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.J Clin Oncol. 2008;26:1275-81.
15. Haffty BG,Yang Q,Reiss M,et al.Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.J Clin Oncol. 2006;24:5652-7.
16. Dent R,Trudeau M,Pritchard KI,et al.Triple-negative breast cancer: clinical features and patterns of recurrence.Clin Cancer Res. 2007;13:4429-34.
17. Berns K,Horlings HM,Hennessy BT,et al.A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.Cancer Cell. 2007;12:395-402.
18. Eichhorn PJ,Gili M,Scaltriti M,et al.Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.Cancer Res. 2008;68:9221-30.
19. Stemke-Hale K,Gonzalez-Angulo AM,Lluch A,et al.An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.Cancer Res. 2008;68:6084-91.
20. Andre F,Job B,Dessen P,et al.Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.Clin Cancer Res. 2009;15:441-51.
21. Fong PC,Boss DS,Yap TA,et al.Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.N Engl J Med. 2009;361:123-34.
22. Ossovskaya V,Koo IC,Kaldjian EP,Alvares C,Sherman BM.Upregulation of poly (ADP-Ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types.Genes Cancer. 2010;1:812-21.
23. Chang CJ,Yang JY,Xia W,et al.EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling.Cancer Cell. 2011;19:86-100.
24. Moreno-Aspitia A,Morton RF,Hillman DW,et al.Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.J Clin Oncol. 2009;27:11-5.
25. Mayer EL,Krop IE.Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.Clin Cancer Res. 2010;16:3526-32.
26. Tryfonopoulos D,Walsh S,Collins DM,et al.Src: a potential target for the treatment of triple-negative breast cancer.Ann Oncol. 2011;22:2234-40.
27. Zhang S,Huang WC,Li P,et al.Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.Nat Med. 2011;17:461-9.
28. Kuroso K,Imai Y,Kobayashi M,et al.Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: correlation with clinicopathological/molecular parameters and prognosis.Pathobiology. 2010;77:231-40.
29. Yom CK,Noh DY,Kim WH,Kim HS.Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer.Breast Cancer Res Treat. 2011;128:647-55.
30. Molckovsky A,Siu LL.First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American Society of Clinical Oncology meeting.J Hematol Oncol. 2008;1:20.
31. Roberts WG,Ung E,Whalen P,et al.Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.Cancer Res. 2008;68:1935-44.
32. Mross K,Stefanic M,Gmehling D,et al.Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.Clin Cancer Res. 2010;16:311-9.
33. Huynh H.Molecularly targeted therapy in hepatocellular carcinoma.Biochem Pharmacol. 2010;80:550-60.
34. Walsh C,Tanjoni I,Uryu S,et al.Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.Cancer Biol Ther. 2010;9:778-90.
35. Turner N,Lambros MB,Horlings HM,et al.Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.Oncogene. 2010;29:2013-23.
36. Dowlati A,Gray R,Sandler AB,Schiller JH,Johnson DH.Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study.Clin Cancer Res. 2008;14:1407-12.
37. Bieche I,Onody P,Laurendeau I,et al.Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications.Clin Chem. 1999;45:1148-56.
38. Bieche I,Parfait B,Laurendeau I,Girault I,Vidaud M,Lidereau R.Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.Oncogene. 2001;20:8109-15.
39. Bieche I,Parfait B,Le Doussal V,et al.Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.Cancer Res. 2001;61:1652-8.
40. Paik S,Shak S,Tang G,et al.A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.N Engl J Med. 2004;351:2817-26.
41. McNeill RE,Miller N,Kerin MJ.Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer.BMC Mol Biol. 2007;8:107.